ArticleJournal of gynecologic oncology2026
Primary chemoradiation versus radical hysterectomy with lymphadenectomy for stage IIICr cervical cancer without parametrial involvement: gynecologic oncology research investigators collaboration study (GORILLA-1002).
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo compare the effectiveness and adverse events of primary chemoradiation versus radical hysterectomy with pelvic or para-aortic lymphadenectomy in patients with 2018 International Federation of Gynecology and Obstetrics stage IIICr cervical cancer without clinical parametrial involvement.
methodsThis retrospective study included patients diagnosed with stage IIICr cervical cancer who had pelvic or para-aortic lymph nodes measuring at least 1 cm in short diameter on preoperative imaging between 2000 and 2020. Primary chemoradiation consisted of external beam radiation therapy and brachytherapy, while adjuvant chemoradiation following radical surgery was administered based on pathological results.
resultsA total of 204 patients underwent primary chemoradiation (n=66) or radical hysterectomy with systematic lymphadenectomy (n=138). There were no significant differences in disease stage or histological type between the groups. In patients with tumors ≥4 cm, primary chemoradiation improved progression-free survival (PFS) compared to radical surgery (5-year survival: 91.1% vs. 61.7%; p<0.005). Favorable factors for PFS included stage IIIC1 disease, primary chemoradiation, and tumor size <4 cm. Stage IIIC1 was associated with better PFS and overall survival than stage IIIC2 (p=0.048 and p=0.020, respectively). Central recurrence was more common after primary chemoradiation, while pelvic sidewall or distant recurrence was more frequent after radical hysterectomy with lymphadenectomy (p=0.009). Anemia was more frequent in the primary chemoradiation group, while lymphedema was less common than in the radical surgery group.
conclusionPrimary chemoradiation may be more effective than radical hysterectomy with systematic lymphadenectomy in patients with stage IIICr cervical cancer without parametrial invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.